Testing effectiveness (Phase 2)Not Yet RecruitingNCT07789873
What this trial is testing
A 28-Day Study of GAL-101 in Participants With Mild to Moderate Alzheimer's Disease
Who this might be right for
Mild to Moderate Alzheimer's Disease
Galimedix Therapeutics Inc 100